Drug intelligence / Profile preview

GATE-301

Development stage: Preclinical
Lead developer: Gate Neurosciences
Modality: Small Molecules

Overview

GATE-301 is a small molecule insulin-like growth factor binding protein 2 (IGFBP2) mimetic being developed by Gate Neurosciences for the treatment of neurodegenerative and neurodevelopmental disorders. IGFBP2 is a key regulator of insulin-like growth factor (IGF) signaling, which plays a vital role in neuronal survival, synaptic plasticity, and cognitive function. By mimicking the activity of IGFBP2, GATE-301 is designed to enhance these neuroprotective pathways and restore synaptic health. The program is part of Gate Neurosciences' broader synaptic medicine portfolio, which includes research conducted at the Falk Center for Molecular Therapeutics at Northwestern University.

Targets

IGFBP2 (Insulin-like growth factor binding protein II)

Beyond the preview

Go deeper on GATE-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GATE-301.

Explore the full profile